- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00935844
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States
- The University of Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Pennsylvania
-
Rockledge, Pennsylvania, United States, 19046
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each patient must meet all of the following criteria to be enrolled in the study:
- ECOG performance status of < or equal to 2.
- Diagnosis of solid tumor malignancy or lymphoma for which standard treatment is no longer effective.
- Have a radiographically or clinically evaluable tumor or lymphoma.
- Measurable disease as described in the protocol.
- Suitable venous access for the study-required blood sampling.
- Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse.
- Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse.
- Voluntary written consent.
- Weigh at least 45 kg.
- Recovered from the reversible effects of prior antineoplastic therapy.
- Meet clinical laboratory values during the screening period as specified in the protocol.
- Left ventricular ejection fraction (LVEF) > or equal to 50% by echocardiogram or multiple acquisition scan (MUGA).
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
- Diagnosis of primary CNS malignancy or carcinomatous meningitis.
- Patient has symptomatic brain metastasis.
- Prior bone allogeneic bone marrow or stem cell transplant.
- Prior radiotherapy involving > or equal to 30% of the hematopoietically active bone marrow, within 21 days before the start of the study drug.
- Systemic antineoplastic therapy within 28 days before the start of the study drug, except for luteinizing hormone-releasing-hormone (LHRH) agonist therapy.
- Exposure to nitrosureas or mitomycin C within 42 days before the start of the study drug.
- Treatment with monoclonal antibodies within 28 days before the start of the study drug.
- Known allergy or hypersensitivity to compounds of similar chemical composition to TAK-901 or its excipient, Captisol.
- Female patients who are lactating or who have a positive serum pregnancy test during the screening period or a positive serum pregnancy test during the screening period.
- Myocardial infarction within 6 months before enrollment.
- Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Abnormalities on 12-lead electrocardiogram (ECG) as specified in the protocol.
- Infection requiring systemic anti-infective therapy within 14 days before the start of study drug.
- Known human immunodeficiency virus (HIV)positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
- Diagnosed or treated for another malignancy within 2 years before the start of study drug or previously diagnosed with another malignancy and have any evidence of residual disease.
- Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment.
- Treatment with any investigational products within 28 days before the first dose of study drug.
- Systemic use of strong CYP3A inhibitors or inducers (as specified in the protocol) within 14 days before the first dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAK-901 Arm
|
This study consists of three sequential parts. Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle. Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle. Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To identify the MTD of TAK-901 administered as either a 3-hour or 1-hour infusion.
Time Frame: 12 months
|
12 months
|
To adaptively adjust the estimate of the MTD of TAK-901 from the escalation phase in an expansion cohort of subjects.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the pharmacokinetic profile of TAK-901 and its primary metabolite (M-I).
Time Frame: 12 months
|
12 months
|
To evaluate disease response.
Time Frame: 12 months
|
12 months
|
To investigate the effect of TAK-901 on tumor proliferation.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C19001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on TAK-901
-
Millennium Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced PolycythemiaUnited States
-
Stemline Therapeutics, Inc.CompletedStudy of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid TumorsAdvanced Solid TumorUnited Kingdom
-
ADC Therapeutics S.A.Active, not recruitingAdvanced Solid TumorsUnited States, Spain, United Kingdom
-
Urovant Sciences GmbHCompletedOveractive BladderUnited States, Spain, Canada, Portugal, Poland, Belgium, Hungary, Lithuania
-
Urovant Sciences GmbHCompletedIrritable Bowel SyndromeUnited States
-
Urovant Sciences GmbHCompletedOveractive BladderUnited States, Poland
-
Reata, a wholly owned subsidiary of BiogenRecruitingA Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS)Diabetic Peripheral Neuropathic PainUnited States
-
Aerami TherapeuticsCompletedPulmonary Arterial HypertensionAustralia
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Dartmouth-Hitchcock Medical CenterMuhimbili University of Health and Allied SciencesCompleted